Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India

Clinical Infectious Diseases

Volumn 50, Issue 3, 2010, Pages 416-425

  Bender, Melissa A ^a,d   Kumarasamy, Nagalingeswaran ^h   Mayer, Kenneth H ^g   Wang, Bingxia ^a,d   Walensky, Rochelle P ^a,b,d   Flanigan, Timothy ^g   Schackman, Bruce R ^f   Scott, Callie A ^a   Lu, Zhigang ^a   Kenneth, A ^a,c,d,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g MIRIAM HOSPITAL   (United States)

^h YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LACTIC ACIDOSIS; LIPODYSTROPHY; MALE; MEDICAL PRACTICE; MORTALITY; NEPHROTOXICITY; NEUROPATHY; PANCREATITIS; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADENINE; ADULT; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HUMANS; INDIA; MALE; PHOSPHONIC ACIDS; STAVUDINE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 75749104632     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649884     Document Type: Article

References (40)

1. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2008. Available at: http://aidsin.fb.nih.gov/contentnles/Adultand AdolescentGL.pdf. Accessed 13 March 2009.
2. World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. 2006. Available at: http://www.who.int/hiv/pub/guidelines/adult/en/index.html. Accessed 13 March 2009.
3. The Clinton Foundation. Antiretroviral (ARV) price list. 2008. Available at: http://www.clintonfou.ndation.org/download/?guid; = 62e82ddc -98de-102b-be34-001143e0d9b6. Accessed 13 March 2009.
4. 4. Kumarasamy N, Venkatesh KK, Cecelia AJ, et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS 2008; 22(4):337-344. (Pubitemid 351562965)
5. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36(8):1070-1073.
6. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354(3):251-260.
7. Doctors Without Borders. Gilead's tenofovir "access program" for developing countries: a case of false promises? 2006. Available at: http: //www.doctorswithoutborders.org/pr/2006/02-07-2006.cfm Accessed 13 March 2009.
8. Mwango A, Giganti M, Mulenga L, et al. First-line tenofovir ART: Zambia. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada. 2009. Abstract 142:19.
9. National AIDS Control Organization. National AIDS control programme-phase III [2006-2011]. Strategy and implementation plan. 2006. Available at: http://www.nacoonli.ne.org/upload/Publication/Strategy%20and%20Implementation%20Plan%20-%20NACO%20 Programme%20Phase%20III%20(2006-2011)%202006.pdf. Accessed 13 March 2009.
10. 10. Freedberg KA, Kumarasamy N, Losina E, et al. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 2007; 21(Suppl 4):S117-S128. (Pubitemid 47051757)
11. National AIDS Control Organization. Antiretroviral therapy guidelines for HIV-infected adults and adolescents including postexposure prophylaxis. May 2007. Available at: http://www.nacoonline.org/upload/Publication/Treatment%20Care%20and%20support/Antiretroviral%20 Therapy%20Guidelines%20fbr%20HIV-Intected%20Adults%20and%20 Adolescents%20Inc.luding%20Post-exposure.pdf. Accessed 13 March 2009.
12. Kumarasamy N, Venkatesh K, Devaleenol B, et al. Safe substitution to AZT among HIV-infected patients initiated on d4T containing HAART from a resource-limited setting. Int J Infect Dis 2009. Available at http://www.ijidonline.com/article/S1201-9712(09)00072-1/abstract. Accessed 31 March 2009.
13. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996.
14. Homan R, Ganesh A, Duraisamy P, et al. Economic analyses of YRG CARE services: implications for program sustainability. Research Triangle Park, NC: Family Health International, 2000.
15. 15. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med 2006; 355:1141-1153. (Pubitemid 44394920)
16. Cecelia AJ, Christybai P, Anand S, et al. Usefulness of an observational database to assess antiretroviral treatment trends in India. Natl Med J India 2006; 19(1):14-17.
17. Wang B, Kumarasamy N, Divi N, et al. Incidence of opportunistic infections (OIs) within specific CD4 strata in HIV-infected patients in Southern India. In: Program and abstracts of the 16th International AIDS Conference. Toronto, Canada. 2006. Abstract WePe0279.
18. International Monetary Fund. World Economic Outlook Database: report for selected countries and subjects. 2008. Available at: http://www. imf.org/external/pubs/ft/weo/2004/01/data/dbcoutm.cfm.Accessed 13 March 2009.
19. 19. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005; 38(2):174-179. (Pubitemid 40189324)
20. 20. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19(7):685-694. (Pubitemid 40593073)
21. 21. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologie failures. AIDS 2006; 20(5):711-718. (Pubitemid 43884298)
22. Y. R. Gaitonde Centre for AIDS Research and Education (YRG CARE) Pharmacy. Unit costs for components of HIV-related health care 2005. Chennai, India: YRG CARE Pharmacy.
23. 23. Reid A, Stohr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008; 46(8): 1271-1281. (Pubitemid 351589914)
24. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40(8):1194-1198.
25. 25. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health-state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002; 22(1):27-38. (Pubitemid 34087688)
26. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994; 14(3):259-265.
27. 27. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292(2):191-201. (Pubitemid 38917996)
28. 28. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364(9428):29-34. (Pubitemid 38968622)
29. 29. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21(10):1273-1281. (Pubitemid 46883481)
30. 30. Sural S, Sharma RK, Singhal MK, et al. Acute renal failure in an intensive care unit in India-prognostic factors and outcome. J Nephrol 1999; 12(6):390-394. (Pubitemid 30014652)
31. Rosen S, Long L, Fox M., Sanne I. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr 2008; 48(3):334-344.
32. 32. Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002; 31(Suppl 3):S140-S144. (Pubitemid 35453575)
33. 33. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15(18):2441-2444. (Pubitemid 34014613)
34. 34. Corless IB, Kirksey KM, Kemppainen J, et al. Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS. AIDS Patient Care STDS 2005; 19(9):577-586. (Pubitemid 41338913)
35. 35. Boulle A, Orrel C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12:753-760. (Pubitemid 47235489)
36. 36. Lapadula G, Costarelli S, Quiros-Roldan E, et al. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis 2008; 46(7):1127-1129. (Pubitemid 351589888)
37. Rey D, Schmitt MP, Hoizey G, et al. Early virologic nonresponse to once daily combination of lamivudine, tenofovir, and nevirapine in ART-naive HIV-infected patients: preliminary results of the DAUFIN study. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA. 2007. Abstract 503:71.
38. Towner W, Kerrigan HL, LaRiviere M., et al. Efficacy of a once-daily (QD) regimen of nevirapine (NVP), lamivudine (3TC), and tenofovir (TDF) in treatment-naive HIV-infected patients: a pilot study. In: Program and abstracts of the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland. 2004. Abstract P49.
39. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359(23):2442-2455.
40. 40. Kohli RM, Sane S, Kumar K, Paranjape RS, Mehendale SM. Assessment of quality of life among HIV-infected persons in Pune, India. Qual Life Res 2005; 14(6):1641-1647. (Pubitemid 40848244)